(Total Views: 717)
Posted On: 03/04/2024 9:53:14 PM
Post# of 148870
Quote:
Ohm, given LL's innate science, I wonder if you have settled on a favored LL trial design and disease combination that best suits LL's strengths and weaknesses?
With the financial constraints that Cytodyn has a trial for inflammation activation in HIV is a good choice. Fast, inexpensive and it will further elucidate leronlimab's mechanism of action. If those financial limits weren't in place a better option would be simultaneous trials in MASH, Long Covid and in any cancer that exhibits a high level of CCR5.
(18)
(0)Scroll down for more posts ▼
